MEDTRACK

16.5K posts

MEDTRACK banner
MEDTRACK

MEDTRACK

@OncoReporte

Welcome to #MedTrack — a free, open platform built for and by healthcare providers & stakeholders. Our mission is to keep the Medical community connected!

Worldwide Beigetreten Şubat 2019
218 Folgt985 Follower
Angehefteter Tweet
MEDTRACK
MEDTRACK@OncoReporte·
DAY 2 Statistics for #ESMO25 🇩🇪 Berlin Stats taken Oct 18 6:10 PM CET 8⃣7⃣.5⃣ Million Impressions 5⃣.3⃣K Posts
OncoAlert@OncoAlert

A Great Day 2 of #ESMO25 Our most sincere thanks to the @myESMO Faculty and Staff for an amazing day of the Congress. ✅87.5 Million Impressions🌐 ✅5.3K Posts Indeed an Amazing meeting in BERLIN🇩🇪 WE ARE ALL OncoAlert🚨 👉Stats Powered by MedTrackSocial.com Free and No Registration Required @DrChoueiri @urotoday @Annals_Oncology @drenriquegrande @MyriamChalabi @nataliagandur @OncLive @DanaFarber @tompowles1 @FernandoOnco @ElisaAgostinett @neerajaiims @PGrivasMDPhD @DrYukselUrun @to_be_elizabeth @HHorinouchi @matteolambe @AndreaNecchi @Erman_Akkus @FadiHaddad_MD @lucarecco @GaiaGriguolo @crisbergerot @CParkMD @oncologician @LorenzaRimassa @RenoHemonc @StephenVLiu @PauloBergerot @cdanicas @AndresFCardonaZ @MedwatchKate

English
0
1
6
1.1K
MEDTRACK retweetet
Elisa Agostinetto
Elisa Agostinetto@ElisaAgostinett·
Thank you @BreastEuropean for highlighting our work at #EBCC15 It was a true pleasure to present our findings on circulating tumor DNA in patients with early #breastcancer treated with neoadjuvant treatment @OncoAlert
Elisa Agostinetto tweet media
European Breast Cancer Conference (EBCC-15)@BreastEuropean

News from #EBCC15: Tumour DNA circulating in patients’ blood after pre-surgery treatments predicts whether breast cancer will return ow.ly/9Tax50YzyBn

English
0
11
29
2.6K
MEDTRACK retweetet
OncoAlert
OncoAlert@OncoAlert·
OncoAlert 🚨 Coverage of DAY THREE of #EBCC15 BRAVE-HEART: Clinical and dosimetric validation of Active Breath Control for cardiac sparing in breast cancer radiotherapy Presented by our OncoAlert Faculty Elisabetta Bonzano Cardiac exposure remains a major determinant of long‑term morbidity and mortality in left‑sided #BreastCancer radiotherapy☢️ and the BRAVE‑HEART trial evaluated the clinical, dosimetric, and practical impact of Deep Inspiration Breath Hold using the Active Breathing Coordinator (ABC). In this ambispective single‑centre study of 400 patients treated across three fractionation schedules, ABC‑DIBH significantly reduced heart and LAD doses compared with free breathing, with large effect sizes and consistent benefit confirmed through intra‑patient paired replanning. Model‑based NTCP analysis demonstrated an approximate halving of predicted late cardiac mortality with ABC, while breath‑hold performance metrics showed high feasibility and reproducibility, including in elderly patients. Together, these findings confirm ABC‑assisted DIBH as a robust, clinically meaningful, and widely feasible strategy to improve cardiac safety in left‑sided breast cancer radiotherapy. @itrisabel @JavierCortesMD @MIgnatiadis @MichaelGnant @Icro_Meattini @matteolambe @c_sotiriou @aftimosp @MOliveira_MD @CarmenCriscit @lab_kok @to_be_elizabeth @ElisaAgostinett @Lucarecco @FernandoOnco @GaiaGriguolo @JankovicK @acampsmalea @kevinpunie @CarmineDeA1 @LauBuisseret @TanjaSpanic
OncoAlert tweet mediaOncoAlert tweet mediaOncoAlert tweet mediaOncoAlert tweet media
English
0
14
16
805
MEDTRACK retweetet
OncoAlert
OncoAlert@OncoAlert·
OncoAlert 🚨 Coverage of DAY THREE of #EBCC15 De-escalating treatment for low-risk Ductal Carcinoma In Situ: early safety of active surveillance without endocrine therapy in the prespecified interim analysis of the LORD-trial Presented by Jelle Wesseling Early results from the LORD trial, presented at the 15th European #BreastCancer Conference (EBCC15) in Barcelona, suggest that active surveillance may be a safe alternative to immediate surgery for women with low‑risk ductal carcinoma in situ (DCIS). The study followed 1,423 patients with screen-detected, grade 1 or 2 DCIS across around 60 hospitals in The Netherlands, comparing standard surgical treatment with close monitoring. After an average follow-up of two years, invasive breast cancer was diagnosed in 9% of patients who had immediate surgery and 6% of those under active surveillance, with no evidence that cancers detected during surveillance were more aggressive. While tumours identified in the surveillance group were slightly larger, outcomes were comparable, leading researchers to describe the findings as reassuring. The results support ongoing efforts to reduce overtreatment in breast cancer care, though longer follow-up is needed before any changes to clinical guidelines are considered. @itrisabel @JavierCortesMD @MIgnatiadis @MichaelGnant @Icro_Meattini @matteolambe @c_sotiriou @aftimosp @MOliveira_MD @CarmenCriscit @lab_kok @to_be_elizabeth @ElisaAgostinett @Lucarecco @FernandoOnco @GaiaGriguolo @JankovicK @acampsmalea @kevinpunie @CarmineDeA1 @LauBuisseret @TanjaSpanic
OncoAlert tweet mediaOncoAlert tweet mediaOncoAlert tweet mediaOncoAlert tweet media
English
1
9
12
826
MEDTRACK retweetet
Mario Balsa
Mario Balsa@MarioBalsaMD·
✨ Mini oral session 2 at #ELCC26: SHR-A2009 (HER3 ADC) + aumolertinib in EGFRm NSCLC (Ph1b/2) 🎯 ORR: 72.1% (1L) | 42.9% (≥2L) 📈 Durable responses (DoR up to 15.7 mo) ⚠️ TRAE G≥3: 31.1% (1L) | 59.5% (≥2L) Strong signal for HER3 + EGFR combo🚀 @OncoAlert @myESMO @OncoReporte @_SEOM @gecp_org @Lung_Cancers
Mario Balsa tweet mediaMario Balsa tweet mediaMario Balsa tweet mediaMario Balsa tweet media
English
0
7
10
791
MEDTRACK retweetet
OncoAlert
OncoAlert@OncoAlert·
A Great Start to Day 3 of #EBCC15 🇪🇸Kudos to the @BreastEuropean team on another amazing meeting and our gratitude to our colleagues keeping colleagues worldwide up to date ✅3.7 million impressions @itrisabel @Icro_Meattini @to_be_elizabeth @TanjaSpanic @matteolambe @aftimosp Pinging our Breast Cancer Faculty We Are OncoAlert 🚨 @E_de_Azambuja @DrSGraff @jesusanampa @ErikaHamilton9 @double_whammied @stage4kelly @coffeemommy @itsnot_pink @maryam_lustberg @IBCResearch @kevinpunie @nicolobattisti @raalbany @hoperugo @teamoncology @stolaney1 @LoiSher @SirohiBhawna @jamecancerdoc @JavierCortesMD @JaniceTNBCmets @Prof_Nadia_H @paspears88 @MammaMiaMagazin #OncoAlertAF @acampsmalea @FernandoOnco @ElisaAgostinett @to_be_elizabeth @realbowtiedoc @Lucarecco @GaiaGriguolo @JankovicK @MarioBalsaMD @DrRishabhOnco @Onco_Cifu88
OncoAlert tweet media
English
0
9
16
834
MEDTRACK
MEDTRACK@OncoReporte·
Great Stats from #ELCC26 Reminding Our Colleagues that all Stats can be downloaded from MedTrackSocial.com Free of Charge and No need for Registration!
OncoAlert@OncoAlert

A Great Start to Day 3 of #ELCC26 🇩🇰 Kudos to the @myESMO team on another amazing meeting and our gratitude to our colleagues keeping colleagues worldwide up to date ✅8.3 million impressions @IASLC @Lung_Cancers @JulienMazieres @HHorinouchi @MarioBalsaMD @g_mountzios @HemOncToday @NEJM @GlopesMd @VJOncology @peters_solange @RenoHemonc @tuttsakhil @BRicciutiMD Ping our faculty🚨We Are OncoAlert @ChristianRolfo @NarjustFlorezMD @StephenVLiu @JackWestMD @bmassutis @Tony_Calles @s_couraud @marinagarassino @UmbertoMalapel1 @CharuAggarwalMD @christine_lovly @barlesi @Piuchagarrido @jillfeldman4 @bensolomon1 @VanitaNoronha @DrSanjayPopat @alexdrilon @JordiRemon @DrJNaidoo @caliraf @MartinReck2 @Latinamd #OncoAlertAF @nataliagandur @FernandoOnco @to_be_elizabeth @realbowtiedoc @DrMirallas @UOzkerim @DrRishabhOnco @Onco_Cifu88

English
0
1
2
151
MEDTRACK retweetet
Biagio Ricciuti, MD, PhD
Biagio Ricciuti, MD, PhD@BRicciutiMD·
The latest @OncoAlert 🚨Newsletter (Mar 20–26, 2026) highlights new key trials shaping the field. Register 👉 buff.ly/7Jlzp0V Featuring: CALYPSO, TAILORx (AI validation), RAGNAR/LUC2001 (FGFR), RECAST, TROPION-Lung02, ORCHARD @GlopesMd @bmassutis @UmbertoMalapel1 @g_mountzios @DrChoueiri @neerajaiims @jillfeldman4 @matteolambe @aftimosp @E_de_Azambuja @hoperugo @stolaney1 @JaniceTNBCmets @apolo_andrea @PGrivasMDPhD @amerseburger @sonpavde @drenriquegrande @tompowles1 @nataliagandur @cdanicas @brian_rini @CathyEngMD @agz_eriksson @womenofteal #ELCC26 #EBCC15 #OncoAlertAF @FernandoOnco @ElisaAgostinett @to_be_elizabeth @realbowtiedoc @Erman_Akkus @MarioBalsaMD @UOzkerim @DrRishabhOnco @Onco_Cifu88
OncoAlert@OncoAlert

The OncoAlert🚨Newsletter Covering March 20-26, 2026 REGISTER TO GET IT 👉 buff.ly/7Jlzp0V or OncoAlert360.com 🚨 This week’s Spotlight is all about trials making waves 🔵 CALYPSO – Savolitinib + durvalumab in papillary renal cancer 🧬 TAILORx – AI validation for breast cancer recurrence prediction 💊 RAGNAR & LUC2001 – Erdafitinib in FGFR-altered cholangiocarcinoma 🟢 RECAST (WJOG9216G) – FOLFIRI vs FOLFOXIRI + ramucirumab in mCRC 🫁 TROPION-Lung02 – Dato-DXd + pembrolizumab in advanced NSCLC 🎯 ORCHARD – Durvalumab + chemo post-osimertinib in EGFR-mutated NSCLC Join nearly 10,000 oncology colleagues — with a 55–60% weekly open rate — and stay up to date with the latest in oncology. @GlopesMd @bmassutis @UmbertoMalapel1 @g_mountzios @BRicciutiMD @DrChoueiri @neerajaiims @jillfeldman4 @matteolambe @aftimosp @E_de_Azambuja @hoperugo @stolaney1 @JaniceTNBCmets @apolo_andrea @PGrivasMDPhD @amerseburger @sonpavde @drenriquegrande @tompowles1 @nataliagandur @cdanicas @brian_rini @CathyEngMD @agz_eriksson @womenofteal #ELCC26 #EBCC15 #OncoAlertAF @FernandoOnco @ElisaAgostinett @to_be_elizabeth @realbowtiedoc @Erman_Akkus @MarioBalsaMD @UOzkerim @DrRishabhOnco @Onco_Cifu88

English
1
12
17
1.7K
MEDTRACK retweetet
Tanja Spanic
Tanja Spanic@TanjaSpanic·
Survivorship starts at diagnosis. #EBCC15, we highlighted how surgeons, radiation therapists, medical oncologists & patient advocates must work together to tailor early breast cancer treatment—around both clinical needs and patient voices. @OncoAlert @europadonna @EORTC_BCG
Tanja Spanic tweet mediaTanja Spanic tweet mediaTanja Spanic tweet mediaTanja Spanic tweet media
English
1
5
12
1K
MEDTRACK retweetet
OncoAlert
OncoAlert@OncoAlert·
Dear Colleagues at #EAU26 We invite you to IKCS Europe 2026🌍Transforming #KidneyCancer Research👉 buff.ly/FNsl4oj Join the International Kidney Cancer Symposium (IKCS): Europe in Paris, France🇫🇷 bringing together global leaders in kidney cancer to explore cutting-edge research, clinical innovation, and future directions in care. 🗓 April 16–18, 2026 📍 Paris Marriott Rive Gauche | Paris, France 🔬 Multidisciplinary science 🎓 CME credits available 🤝 Academia, clinicians, industry & advocacy Coverage by OncoAlert Here is Dr. Laurence Albiges to tell us more Be part of the conversation shaping the future of kidney cancer care. @salvolarosa @AlbigesL @HaanenJohn @BarbaraJereczek @will_oncology @DrIacovelli @EJonasch @Ric_Campi @danieleamparore @GaelleMargue @hannahrwarren Jean Emmanuel Bibault @HopitalPompidou @marc_eid @Tom_J_Mitchell @CPRT65 @enrique_trilla @schmidingerRCC @GEVaughan1 @KidneyCancer
English
0
3
7
425
MEDTRACK retweetet
OncoAlert
OncoAlert@OncoAlert·
OncoAlert 🚨 Coverage of DAY TWO of #EBCC15 Cost-effectiveness of contrast enhanced mammography for women with extremely dense breasts in a national breast cancer screening program Presented by Dr. Mengmeng Li This study assessed whether contrast‑enhanced mammography (CEM) is a cost‑effective alternative to digital mammography (DM) for population‑based screening of women aged 50–74 with extremely dense breasts, a group at higher cancer risk and reduced DM sensitivity. Using an updated SiMRiSc micro‑simulation model that accounted for age‑related decreases in breast density, biennial CEM screening (with a switch back to DM once density declined to BI‑RADS C) was compared with standard biennial DM. CEM detected 25% more tumours and reduced breast cancer mortality and interval cancers by 18% and 41%, respectively, although it increased false positives and slightly raised the risk of radiation‑induced tumours. With an incremental cost‑effectiveness ratio of €12,224 per life‑year gained—well below the €20,000 willingness‑to‑pay threshold—biennial CEM was found to be a cost‑effective screening strategy for women with extremely dense breasts. #BreastCancer @itrisabel @JavierCortesMD @MIgnatiadis @MichaelGnant @Icro_Meattini @matteolambe @c_sotiriou @aftimosp @MOliveira_MD @CarmenCriscit @lab_kok @to_be_elizabeth @ElisaAgostinett @Lucarecco @FernandoOnco @GaiaGriguolo @JankovicK @acampsmalea @kevinpunie @CarmineDeA1 @LauBuisseret @TanjaSpanic
OncoAlert tweet mediaOncoAlert tweet mediaOncoAlert tweet mediaOncoAlert tweet media
English
0
8
14
813
MEDTRACK retweetet
OncoAlert
OncoAlert@OncoAlert·
OncoAlert 🚨 Coverage of DAY TWO of #EBCC15 Efficacy of elinzanetant for the treatment of vasomotor symptoms in women with #BreastCancer : Subgroup analysis of the OASIS-4 trial by type of Endocrine Therapy Presented by Dr. Fatima Cardoso "New data from the OASIS 4 clinical trial show that elinzanetant, a non‑hormonal drug targeting neurokinin, provides sustained relief from moderate‑to‑severe hot flushes and night sweats in women receiving endocrine therapy for hormone receptor–positive breast cancer, regardless of the type of endocrine treatment used. The analysis found rapid and durable reductions in both frequency and severity of vasomotor symptoms across patients taking tamoxifen, aromatase inhibitors, and those with or without ovarian function suppression, with benefits maintained for up to 52 weeks. Elinzanetant was generally well tolerated, with mostly mild to moderate side effects, and by improving vasomotor (hot flushes) symptom control without hormonal intervention, it may help patients better adhere to their cancer treatment and potentially improve long-term outcomes. @itrisabel @JavierCortesMD @MIgnatiadis @MichaelGnant @Icro_Meattini @matteolambe @c_sotiriou @aftimosp @MOliveira_MD @CarmenCriscit @lab_kok @to_be_elizabeth @ElisaAgostinett @Lucarecco @FernandoOnco @GaiaGriguolo @JankovicK @acampsmalea @kevinpunie @CarmineDeA1 @LauBuisseret @TanjaSpanic
OncoAlert tweet mediaOncoAlert tweet mediaOncoAlert tweet mediaOncoAlert tweet media
English
1
13
16
816
MEDTRACK retweetet
OncoAlert
OncoAlert@OncoAlert·
OncoAlert 🚨 Coverage of DAY TWO of #EBCC15  Automated recurrence risk stratification in breast cancer using a multimodal MRI–report–clinical deep learning model Presented by Dr. Chunyao Lu Accurate prediction of breast cancer recurrence remains challenging using pathology and clinical factors alone, prompting the development of a multimodal deep learning model that integrates DCE breast MRI, radiology report text, and structured clinical data for individualized risk stratification. In a retrospective cohort of 3,266 women with primary breast cancer, the model jointly analyzed early MRI enhancement features, transformer‑encoded radiologist descriptions, and baseline clinical variables to predict time‑to‑recurrence. The fully fused MRI–report–clinical model demonstrated superior prognostic performance (C‑index 0.715) compared with unimodal and partially combined approaches, identifying a high‑risk subgroup with a more than five‑fold increased hazard of local, regional, or distant recurrence. These findings suggest that incorporating radiological reasoning captured in reports alongside imaging and clinical data enables more precise, automated post‑treatment recurrence risk stratification with potential implications for personalized surveillance and management. #BreastCancer @itrisabel @JavierCortesMD @MIgnatiadis @MichaelGnant @Icro_Meattini @matteolambe @c_sotiriou @aftimosp @MOliveira_MD @CarmenCriscit @lab_kok @to_be_elizabeth @ElisaAgostinett @Lucarecco @FernandoOnco @GaiaGriguolo @JankovicK @acampsmalea @kevinpunie @CarmineDeA1 @LauBuisseret @TanjaSpanic
OncoAlert tweet mediaOncoAlert tweet mediaOncoAlert tweet mediaOncoAlert tweet media
English
1
9
10
978
MEDTRACK retweetet
Gil Morgan, MD
Gil Morgan, MD@weoncologists·
As part of the OncoCollective🌐 & @OncoAlert 🚨 I am Proud to Present this Great group‼️ The #OncoCollective — a global initiative bringing together experts in patient advocacy, clinical care, policy, and health economics to break down barriers to optimal cancer care. @ArBayle
OncoAlert@OncoAlert

🚨 Introducing the #OncoCollective — a global initiative bringing together experts in patient advocacy, clinical care, policy, and health economics to break down barriers to optimal cancer care. In this video (OncoCollective 101), Dr. Arnaud Bayle @ArBayle 🇫🇷breaks down what the OncoCollective is, its goals, and how it's driving change! Focus areas include precision medicine, data & evidence, and access policy — with recent work tackling barriers in relapsed/refractory multiple myeloma. Because innovation should translate into real benefits for patients worldwide. 🌍 @OncoAlert 🚨is a Proud Partner to the OncoCollective!! To Learn more 📩👉 hilary.hansen@sanofi.com @NorthTxMSG @elisaoehrlein @ac_palmer @elias_martine @weoncologists @ArBayle @KashyappatelMd

English
0
4
5
674
MEDTRACK retweetet
Elisabetta Bonzano MD, PhD
Elisabetta Bonzano MD, PhD@to_be_elizabeth·
📌 Day2 at #EBCC15 ✨Survivorship Starts at Diagnosis: Tailoring Treatment for Early Breast Cancer ✨ “Improving Shared Decision Making to Optimise Surgery”✨ 🎙️ great talk led by Shelley Potter 👏🏻 @OncoAlert #OncoAlertAF
Elisabetta Bonzano MD, PhD tweet mediaElisabetta Bonzano MD, PhD tweet mediaElisabetta Bonzano MD, PhD tweet mediaElisabetta Bonzano MD, PhD tweet media
English
0
9
10
625

Entdecken

@BreastEuropean @OncoAlert @itrisabel @JavierCortesMD @MIgnatiadis @MichaelGnant @Icro_Meattini @matteolambe